Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on April 28, 2004, reporting an event that occurred on April 27, 2004. The filing is brief, indicating "Other Events and Required FD Disclosure" as the sole item. Without further details within this specific 8-K excerpt, it's challenging to provide in-depth operational or financial insights. However, for investors, the significance of this filing lies in its timing and the company's adherence to disclosure requirements. Any "Other Events" or "Required FD Disclosures" in SEC filings can potentially impact a company's stock price and investor confidence. Investors should refer to the full, unredacted filing to understand the specific event that triggered this report and its implications for Regeneron's business strategy, pipeline, or regulatory status.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report on Form 8-K.
- 2The report was filed on April 28, 2004, with the earliest event date being April 27, 2004.
- 3The filing falls under Item 5: Other Events and Required FD Disclosure.
- 4The provided excerpt does not contain specific details about the nature of the event.
- 5The filing indicates the company's principal executive offices are located in Tarrytown, NY.
- 6Regeneron's Commission File Number is 0-19034.